Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$4.73 USD
-0.04 (-0.84%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.82 +0.09 (1.90%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXEO 4.73 -0.04(-0.84%)
Will LXEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LXEO
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Meta, Microsoft upgraded: Wall Street's top analyst calls
Oppenheimer Initiates Coverage on Lexeo Therapeutics (LXEO) with Outperform Rating | LXEO Stock News
Lexeo Therapeutics (LXEO) Receives Positive Start by Oppenheimer
Lexeo Therapeutics initiated with bullish view at Oppenheimer, here's why